Femasys closed a $30.0 million private Placement that issued 5,013,559 common shares, 4,361,440 pre‑funded warrants and 18,749,998 accompanying warrants, expanding its Capital base. The influx of cash strengthens Liquidity but adds dilution, meaning current shareholders own a smaller slice of a still‑volatile stock.

Key Highlights

  • Issued 5,013,559 common shares at $3.20 per share, plus 4,361,440 pre‑funded warrants and 18,749,998 accompanying warrants
  • Insiders purchased $134,000 of stock in five transactions during the prior 60 days
  • Femasys Inc. (NASDAQ: FEMY) completed a private placement that generated roughly $30.0 million in gross proceeds.
  • The transaction added 5,013,559 common shares, 4,361,440 pre-funded warrants, and 18,749,998 accompanying warrants to the capital structure.

Femasys Inc. (NASDAQ: FEMY) completed a private placement on August 10 that generated roughly $30.0 million in gross proceeds. The transaction added 5,013,559 common shares, 4,361,440 pre‑funded warrants and 18,749,998 accompanying warrants to the capital structure.

$30M Private Placement Closes

The private placement agreement, signed on August 7, called for the issuance of an aggregate of 5,013,559 common shares at a purchase price of $3.20 per share. Purchasers also received pre‑funded warrants priced at $3.1999 each, reflecting a $0.0001 discount to the common share price. In addition, the deal bundled two sets of accompanying warrants, each set covering 9,374,999 shares, for a total of 18,749,998 warrants.

These securities collectively represent a sizable capital infusion that will support the company’s development programs. The cash boost improves the Balance Sheet but also increases the total share count, meaning each existing holder now claims a thinner portion of equity.

Securities Structure and Pricing

The pre‑funded warrants are exercisable for a nominal $0.0001 per share, effectively pre‑paying the purchase price and allowing holders to convert to common stock without additional cash outlay. The accompanying warrants split into common warrants, exercisable immediately at $2.95 per share, and milestone warrants, which become exercisable only after the company reaches $1,500,000 of U.S. Revenue in a fiscal quarter and satisfies a price condition of 130% of the $2.95 exercise price for twenty of the thirty preceding trading days. Both Warrant classes include standard anti‑dilution adjustments, protecting investors from future Equity restructurings.

The layered structure incentivizes performance while providing downside protection, yet it introduces complexity that could affect future pricing dynamics.

Market Context and Investor Signal

Peer stocks PMI and NXL fell 3.0% and 1.0% respectively, underscoring sector‑wide weakness that the company must navigate. Insider activity shows executives and directors spent about $134,000 on stock across five purchases in the two months ending August 11, a modest commitment given the company’s $7 million market capitalization. The influx of capital may stabilize operations, yet the extensive warrant grants could further dilute shareholders if exercised, a risk that investors must weigh against the liquidity gain.

Upcoming Governance Milestones

A side letter with lead investor Nantahala Capital Management grants the investor the right to designate up to two board designees, provided certain ownership thresholds are met. However, on August 5 and August 6 the lead lender and lead investor respectively terminated their rights to name board representatives, removing that governance avenue. Future corporate governance will depend on the remaining board composition and any new appointments the company may make.

The next quarterly Earnings release will reveal whether the capital raise translates into revenue growth and whether the company can meet the milestone criteria for the higher‑priced warrants, a development that will shape valuation outlooks.

Peers Moving on This News

  • Picard Medical Inc (NYSE American: PMI) down 3.0%
  • Nexalin Technology Inc (NASDAQ: NXL) down 1.0%